Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Ubiquitin pathway modulator

DRUG CLASS:

Ubiquitin pathway modulator

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ARV-471 Sensitive: B - Late Trials ARV-471 Sensitive : B	ARV-471 Sensitive: B - Late Trials ARV-471 Sensitive : B
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + ARV-471 Sensitive: C3 – Early Trials palbociclib + ARV-471 Sensitive : C3	palbociclib + ARV-471 Sensitive: C3 – Early Trials palbociclib + ARV-471 Sensitive : C3
GSPT1 deletion	Acute Lymphocytic Leukemia	GSPT1 deletion	Acute Lymphocytic Leukemia	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D
ER underexpression + ER Y537S	Breast Cancer	ER underexpression + ER Y537S	Breast Cancer	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D
ER underexpression	Breast Cancer	ER underexpression	Breast Cancer	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D